Sign in
Taking people in United StatesPhase 2

Tests UBT251 in adults living with overweight or obesity

Tests UBT251 against a placebo in adults living with overweight or obesity.

Key facts

Who runs it
Novo Nordisk A/S
Where
Cypress and Overland Park, United StatesSee the 2 sitesAlso in 1 other country, 1 site
Trial code
Registry title
A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity
Status
Recruiting
Phase
Phase 2
People taking part
333 people, planned
Started
2 Feb 2026
Expected to end
18 Feb 2027
Type of study
Interventional, 11 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • UBT251
  • Placebo
Record updated
21 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults living with overweight or obesity to test how safe and effective UBT251 is compared with placebo.

Age
18 to 65 years. Part A: 18-55 years. Part B: 18-65 years. Part C: 18-55 years.
Sex
Men and women (sex at birth).
Disease stage
Overweight or obesity due to excess fat tissue. BMI Part A: 27.0-39.9 kg/m^2. Part B: 30.0-50.0 kg/m^2. Part C: 24-34.9 kg/m^2.
Earlier treatment
Must not have used any marketed GLP-1, GIP or glucagon receptor agonist medicine within 90 days before screening.

Main reasons for not taking part

  • Known or suspected allergy to the study medicine or related products
  • Treatment with a marketed GLP-1, GIP or glucagon receptor agonist medicine within 90 days before screening
  • Any condition that, in the investigator's opinion, could risk safety or following the study plan

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Male or female (sex at birth)
  • For Part C: Japanese, Chinese or non-Asian participants (all self-reported):; For Japanese participants: both parents of Japanese descent; For Chinese participants: both parents of Chinese descent; For non-Asian participants: both parents of non-Asian descent (non-Asian is defined as of countries outside of Asia)
  • Age at the time of signing the informed consent:; For Part A: 18-55 years (both inclusive); For Part B: 18-65 years (both inclusive); For Part C: 18-55 years (both inclusive)
  • BMI at screening (overweight and obesity should be due to excess adipose tissue, as judged by the investigator):; For Part A: 27.0-39.9 kilogram per meter square (kg/m\^2) (both inclusive); For Part B: 30.0-50.0 kg/m\^2 (both inclusive); For Part C: 24-34.9 kg/m\^2 (both inclusive)
  • Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator

Who cannot take part

  • Known or suspected hypersensitivity to study intervention(s) or related products
  • Any condition, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol
  • Treatment with any marketed product containing compounds with glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) or glucagon receptor agonism within 90 days before screening

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

Where in United States

Also in 1 other country, 1 site

  • Altasciences Clinical LA, Inc.Cypress, United StatesContact: Novo NordiskTaking people
  • Altasciences Clinical Kansas, Inc.Overland Park, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

The purpose of this clinical study is to find out if UBT251 is safe and effective for treating people who are living with overweight or obesity. Participants will get either UBT251 (the treatment being tested) or Placebo (a treatment that has no active medicine in it), which treatment participants get is decided by chance.

The 11 groups in the trial

  • Part A - UBT251Treatment being tested

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Treatment: UBT251

  • Part A - placeboPlacebo, for comparison

    Participants will receive placebo matched to UBT251 subcutaneously.

    Treatment: Placebo

  • Part B - Arm A (UBT251)Treatment being tested

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Treatment: UBT251

  • Part B - Arm B (UBT251)Treatment being tested

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Treatment: UBT251

  • Part B - Arm C (UBT251)Treatment being tested

    Participants will be randomized to receive multiple dose levels subcutaneously.

    Treatment: UBT251

  • Part B - Arm D (UBT251)Treatment being tested

    Participants will be randomized to receive 2 dose levels subcutaneously.

    Treatment: UBT251

  • Part B - Arm E (UBT251)Treatment being tested

    Participants will be randomized to receive a single dose level subcutaneously.

    Treatment: UBT251

  • Part B - placeboPlacebo, for comparison

    Participants will receive placebo matching one of the UBT251 arms subcutaneously.

    Treatment: Placebo

  • Part C - UBT251 dose 1Treatment being tested

    Participants will be randomized to receive dose level 1 subcutaneously.

    Treatment: UBT251

  • Part C - UBT251 dose 2Treatment being tested

    Participants will be randomized to receive dose level 2 subcutaneously.

    Treatment: UBT251

  • Part C - UBT251 dose 3Treatment being tested

    Participants will be randomized to receive dose level 3 subcutaneously.

    Treatment: UBT251

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Study Investigating Safety, Tolerability and Efficacy of UBT251 in Participants Living With Overweight or Obesity
Plain-language title
Tests UBT251 in adults living with overweight or obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07395687, who can take part
Record updated
21 April 2026